The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil
Open accessAbstract
Apathy is one of the most common symptoms encountered in Parkinson's disease, and is defined as a lack of motivation accompanied by reduced goal-directed cognition, behaviour and emotional involvement. In a previous study we have described a delayed withdrawal syndrome after successful motor improvement related to subthalamic stimulation allowing for a major decrease in dopaminergic treatment. This withdrawal syndrome correlated with a diffuse mesolimbic dopaminergic denervation. To confirm our hypothesis of parkinsonian apathy being related to mesolimbic dopaminergic denervation, we performed a randomized controlled study using piribedil, a relatively selective D2/D3 dopamine agonist to treat parkinsonian apathy, using the model of postoperative apathy. A 12-week prospective, placebo-controlled, randomized, double-blinded trial was conducted in 37 patients with Parkinson's disease presenting with apathy (Starkstein Apathy Scale score > 14) following subthalamic nucleus stimulation. Patients received either piribedil up to 300 mg per day (n = 19) or placebo (n = 18) for 12 weeks. The primary end point was the improvement of apathy under treatment, as assessed by the reduction of the Starkstein Apathy Scale score in both treatment groups. Secondary end points included alleviation in depression (Beck Depression Inventory), anxiety (Beck Anxiety Inventory), improvement of quality of life (PDQ39) and anhedonia (Snaith-Hamilton Pleasure Scale). Exploratory endpoints consisted in changes of the Robert Inventory score and Hamilton depression scales. An intention to treat analysis of covariance analysis was performed to compare treatment effects (P < 0.05). The number of premature study dropouts was seven in the placebo and five in the piribedil groups, mostly related to intolerance to hypodopaminergic symptoms. At follow-up evaluation, the apathy score was reduced by 34.6% on piribedil versus 3.2% on placebo (P = 0.015). With piribedil, modifications in the Beck depression and anxiety scores were -19.8% and -22.8%, respectively versus +1.4% and -8.3% with placebo, without reaching significance level. Piribedil led to a trend towards improvement in quality of life (-16.2% versus +6.7% on placebo; P = 0.08) and anhedonia (-49% versus -5.6% on the placebo; P = 0.08). Apathy, assessed by the Robert Inventory score, improved by 46.6% on piribedil and worsened by 2.3% on placebo (P = 0.005). Depression, measured by the Hamilton score, improved in the piribedil group (P = 0.05). No significant side effects were observed. The present study provides a class II evidence of the efficacy of the dopamine agonist piribedil in the treatment of apathy in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Clinical Epidemiology: A Basic Science for Clinical Medicine.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-825_9 · Cited by 3,476
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Self-citationKrack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
Self-citationAntidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., & Benabid, A.-L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391603 · Cited by 1,853
Self-citationA scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
What contributes to quality of life in patients with Parkinson's disease?
Schrag, A. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380
Apathy and the Functional Anatomy of the Prefrontal Cortex–Basal Ganglia Circuits
Levy, R., & Dubois, B. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhj043 · Cited by 1,285
Reliability, validity, and clinical correlates of apathy in Parkinson's disease
(1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.2.134 · Cited by 1,185
Remy, P., Doder, M., Lees, A., Turjanski, N., & Brooks, D. (2005) · Brain · doi:10.1093/brain/awh445 · Cited by 1,040
Clinical Epidemiology - a basic science for clinical medicine
Hoffbrand, B. I. (1992) · Postgraduate Medical Journal · doi:10.1136/pgmj.68.806.987-a · Cited by 783
Odekerken, V. J., van Laar, T., Staal, M. J., Mosch, A., Hoffmann, C. F., Nijssen, P. C., Beute, G. N., van Vugt, J. P., Lenders, M. W., Contarino, M. F., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70264-8 · Cited by 763
Witt, K., Daniels, C., Reiff, J., Krack, P., Volkmann, J., Pinsker, M. O., Krause, M., Tronnier, V., Kloss, M., Schnitzler, A., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70114-5 · Cited by 651
Self-citationFunkiewiez, A. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2002.009803 · Cited by 572
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Neuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 557
Thobois, S., Ardouin, C., Lhommee, E., Klinger, H., Lagrange, C., Xie, J., Fraix, V., Coelho Braga, M. C., Hassani, R., Kistner, A., et al. (2010) · Brain · doi:10.1093/brain/awq032 · Cited by 516
Self-citationPluck, G. C. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.636 · Cited by 473
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease
Voon, V., Krack, P., Lang, A. E., Lozano, A. M., Dujardin, K., Schüpbach, M., D’Ambrosia, J., Thobois, S., Tamma, F., Herzog, J., et al. (2008) · Brain · doi:10.1093/brain/awn214 · Cited by 472
Self-citationRobert, P. H., Clairet, S., Benoit, M., Koutaich, J., Bertogliati, C., Tible, O., Caci, H., Borg, M., Brocker, P., & Bedoucha, P. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.755 · Cited by 405
Bodi, N., Keri, S., Nagy, H., Moustafa, A., Myers, C. E., Daw, N., Dibo, G., Takats, A., Bereczki, D., & Gluck, M. A. (2009) · Brain · doi:10.1093/brain/awp094 · Cited by 363
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Rabinak, C. A., & Nirenberg, M. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.294 · Cited by 349
Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J. L., Obeso, J. A., & Bezard, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70287-x · Cited by 335
The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders
Leriche, L., Bezard, E., Gross, C., Guillin, O., Foll, B., Diaz, J., & Sokoloff, P. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706784111551 · Cited by 331
Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours
Lhommée, E., Klinger, H., Thobois, S., Schmitt, E., Ardouin, C., Bichon, A., Kistner, A., Fraix, V., Xie, J., Aya Kombo, M., et al. (2012) · Brain · doi:10.1093/brain/aws078 · Cited by 296
Self-citationApathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom
Czernecki, V., Schüpbach, M., Yaici, S., Lévy, R., Bardinet, E., Yelnik, J., Dubois, B., & Agid, Y. (2008) · Movement Disorders · doi:10.1002/mds.21949 · Cited by 230
Psychosis, apathy, depression and anxiety in Parkinson's disease
Gallagher, D. A., & Schrag, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.041 · Cited by 211
Moreau, C., Delval, A., Defebvre, L., Dujardin, K., Duhamel, A., Petyt, G., Vuillaume, I., Corvol, J.-C., Brefel-Courbon, C., Ory-Magne, F., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70106-0 · Cited by 192
Self-citationPost, R. M. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770290091008 · Cited by 168
Leentjens, A. F. G., Koester, J., Fruh, B., Shephard, D. T. S., Barone, P., & Houben, J. J. G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.01.012 · Cited by 167
Lemke, M. R., Brecht, H. M., Koester, J., Kraus, P. H., & Reichmann, H. (2005) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.17.2.214 · Cited by 163
Évaluation des troubles comportementaux hyper- et hypodopaminergiques dans la maladie de Parkinson
Ardouin, C., Chéreau, I., Llorca, P., Lhommée, E., Durif, F., Pollak, P., & Krack, P. (2009) · Revue Neurologique · doi:10.1016/j.neurol.2009.06.003 · Cited by 152
Self-citationBenito‐León, J., Cubo, E., Coronell, C., & on behalf of the ANIMO Study Group (2012) · Movement Disorders · doi:10.1002/mds.23872 · Cited by 129
Millan, M. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.002 · Cited by 99
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Pondal, M., Marras, C., Miyasaki, J., Moro, E., Armstrong, M. J., Strafella, A. P., Shah, B. B., Fox, S., Prashanth, L. K., Phielipp, N., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302684 · Cited by 99
Apathy in Parkinson's disease: Diagnostic and etiological dilemmas
STARKSTEIN, S. E. (2012) · Movement Disorders · doi:10.1002/mds.24061 · Cited by 93
Effects of Ropinirole on Nonmotor Symptoms of Parkinson Disease: A Prospective Multicenter Study
Rektorová, I., Baláž, M., Svátová, J., Zárubová, K., Honig, I., Dostal, V., Sedláčková, S., Nestrašil, I., Mastík, J., Bareš, M., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31815d25ce · Cited by 79
Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
Rascol, O., Dubois, B., Castro‐Caldas, A., Senn, S. J., Signore, S. D., & Lees, A. J. (2006) · Movement Disorders · doi:10.1002/mds.21122 · Cited by 72
Is depression in Parkinson's Disease (PD) a specific entity?
EVEN, C., & Weintraub, D. A. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.002 · Cited by 61
Castro‐Caldas, A., Delwaide, P. J., Jost, W. H., Merello, M., Williams, A. C., Lamberti, P., Aguilar, M., Signore, S. D., & Césaro, P. (2005) · Movement Disorders · doi:10.1002/mds.20750 · Cited by 56
Dujardin, K., & Defebvre, L. (2012) · Neurology · doi:10.1212/wnl.0b013e3182698dd4 · Cited by 15
Cited by
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Neuroscience of apathy and anhedonia: a transdiagnostic approach
Husain, M., & Roiser, J. P. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0029-9 · Cited by 640
Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment
Pagonabarraga, J., Kulisevsky, J., Strafella, A. P., & Krack, P. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00019-8 · Cited by 549
Self-citationImpulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Voon, V., Napier, T. C., Frank, M. J., Sgambato-Faure, V., Grace, A. A., Rodriguez-Oroz, M., Obeso, J., Bezard, E., & Fernagut, P.-O. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30004-2 · Cited by 359
Metadata
- Authors
- Thobois, S., Lhommée, E., Klinger, H., Ardouin, C., Schmitt, E., Bichon, A., Kistner, A., Castrioto, A., Xie, J., Fraix, V., Pelissier, P., Chabardes, S., Mertens, P., Quesada, J.-L., Bosson, J.-L., Pollak, P., Broussolle, E., & Krack, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-03-29
- Volume
- 136
- Issue
- 5
- Pages
- 1568-1577
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2151615457
- Cited by
- 274
- References
- 46
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.